Xconomy

Get it right the first time. You're a pioneer on the right path forward.

Biopharmaceutical start-ups need to navigate the complex path to commercialization. The combination of an extensive product and services portfolios with expert support and knowledge will allow you: rise above risks, accelerate drug development, and navigate the path to commercialization.

Learn more: https://youtu.be/w8VQQY7XhFc?utm_source=Informa%20Xconomy&utm_medium=EB%20Pathways%20Video&utm_campaign=EB%20Pathways

Eventually most product distribution and patient access programs experience service disruptions, face unforeseen challenges, and receive negative feedback from stakeholders. Why? Download this whitepaper to learn more.

How Healthy Are Your Market Access Programs? A guide to performing check-ups on pharmaceutical distribution and patient access programs

Xconomy Insight's latest whitepaper is ready for download: Learn how a patient-centric, tech-driven approach can broaden access to research/reach patients regardless of geography, ethnicity, s*x, or gender.

Bridging the Diversity Gap with Decentralized Trails How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, s*x, or gender

Solid Biosciences has answered the FDA’s outstanding questions about its Duchenne muscular gene therapy, clearing a clinical trial to now resume after patient complications last year led the agency to halt the study for a second time.

Xconomy: FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume Solid Biosciences has answered the FDA’s outstanding questions about its Duchenne muscular gene therapy, clearing a clinical trial to now resume after

The announcement after the market close on Wednesday follows the May failure of the drug, elafibranor, in a pivotal NASH study.

Xconomy: Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis (NASH) and implementing a corporate restructuring

“We’ll now definitely move it forward in Dravet and have the discussion with the FDA in Lennox-Gastaut ... And with the results in CDKL5 and Dup15q, we believe there is a route forward.”

Xconomy: With Phase 2 Data in Hand, Ovid Eyes Multiple FDA Filings for Epilepsy Drug Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is

Praxis is developing drugs intended to address the misfiring neuronal circuitry at the root of some neurological disorders.

Xconomy: Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs Praxis Precision Medicines kept mostly quiet about its research on central nervous system disorder (CNS) drugs until May, when it emerged from stealth and

Combined Therapeutics Inc Therapeutics Wins $250,000 MilliporeSigma Advance Biotech Grant: https://xconomy.com/national/2020/09/25/combined-therapeutics-wins-250000-milliporesigma-advance-biotech-grant/

The best in biotech.

And the 2020 National Xconomy Awards Winners Are... Congratulations to all the finalists and winners! This year we received over 600 nominations across 10 award categories. Each nomination was carefully

Registration is still open for today's National Xconomy Awards! Sign up now for free and watch the live webcast at 3pm ET + network with 700 life science leaders. Help us celebrate the best in biotech: https://xconomy.bioprocessintl.com/national-xconomy-awards-registration-2020

“We hope to slow down the disease progression, but we do believe our approach has the ability to show improvement,” in cognition and other measures, Kawas says.

Xconomy: Athira CEO Kawas: Alzheimer’s Drug Aims for “Recovery of Brain Function” The key to Athira Pharma’s approach to Alzheimer’s disease is already inside each of us: a repair mechanism that can regenerate damaged neurons. What’s

Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be considered sufficiently different for purposes of awarding orphan drug designation or exclusivity.

Xconomy: Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be